Expression of R132H Mutational IDH1 in Human U87 Glioblastoma Cells Affects the SREBP1a Pathway and Induces Cellular Proliferation

[1]  Yan Ding,et al.  IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma , 2012, Cancer science.

[2]  A. Peraud,et al.  IDH1 mutations in grade II astrocytomas are associated with unfavorable progression‐free survival and prolonged postrecurrence survival , 2012, Cancer.

[3]  G. Riggins,et al.  Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2 , 2012, Current opinion in oncology.

[4]  K. Kinzler,et al.  Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome , 2011, Proceedings of the National Academy of Sciences.

[5]  Karsten Wrede,et al.  Molecular classification of low-grade diffuse gliomas. , 2010, The American journal of pathology.

[6]  K. Guan,et al.  IDH1 mutant structures reveal a mechanism of dominant inhibition , 2010, Cell Research.

[7]  R. Guillevin,et al.  IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas , 2010, Neurology.

[8]  Rui Huang,et al.  Glioma-derived mutations in IDH: from mechanism to potential therapy. , 2010, Biochemical and biophysical research communications.

[9]  S. Horvath,et al.  EGFR Signaling Through an Akt-SREBP-1–Dependent, Rapamycin-Resistant Pathway Sensitizes Glioblastomas to Antilipogenic Therapy , 2009, Science Signaling.

[10]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[11]  T. Tominaga,et al.  Analysis of IDH1 and IDH2 mutations in Japanese glioma patients , 2009, Cancer science.

[12]  K. Hoang-Xuan,et al.  Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Christian Mawrin,et al.  Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas , 2009, Acta Neuropathologica.

[14]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[15]  D. Louis,et al.  Faculty Opinions recommendation of Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. , 2009 .

[16]  Kun-Liang Guan,et al.  Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α , 2009, Science.

[17]  A. Mackay-Sim,et al.  EdU, a new thymidine analogue for labelling proliferating cells in the nervous system , 2009, Journal of Neuroscience Methods.

[18]  Andrey Korshunov,et al.  Analysis of the IDH1 codon 132 mutation in brain tumors , 2008, Acta Neuropathologica.

[19]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[20]  Keith R Solomon,et al.  Cholesterol and Cholesterol-Rich Membranes in Prostate Cancer: An Update , 2008, Tumori.

[21]  Santosh Kesari,et al.  Malignant gliomas in adults. , 2008, The New England journal of medicine.

[22]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[23]  E. Struys.  D-2-Hydroxyglutaric aciduria: Unravelling the biochemical pathway and the genetic defect , 2006, Journal of Inherited Metabolic Disease.

[24]  I. Shechter,et al.  IDH1 gene transcription is sterol regulated and activated by SREBP-1a and SREBP-2 in human hepatoma HepG2 cells: evidence that IDH1 may regulate lipogenesis in hepatic cells. , 2003, Journal of lipid research.

[25]  Jan B. Vermorken,et al.  Comparison of the sulforhodamine B assay and the clonogenic assay for in vitro chemoradiation studies , 2003, Cancer Chemotherapy and Pharmacology.

[26]  E. Gabrielson,et al.  Regulation of fatty acid synthase expression in breast cancer by sterol regulatory element binding protein-1c. , 2003, Experimental cell research.

[27]  G. Gimpl,et al.  A closer look at the cholesterol sensor. , 2002, Trends in biochemical sciences.

[28]  Joseph L Goldstein,et al.  SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. , 2002, The Journal of clinical investigation.

[29]  D Tabor,et al.  Regulation of gene expression by SREBP and SCAP. , 2000, Biochimica et biophysica acta.

[30]  G. Semenza,et al.  Expression of hypoxia‐inducible factor 1α in brain tumors , 2000 .

[31]  M. Brown,et al.  A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Goldstein,et al.  The SREBP Pathway: Regulation of Cholesterol Metabolism by Proteolysis of a Membrane-Bound Transcription Factor , 1997, Cell.

[33]  F. Ducray,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[34]  M. Aghili,et al.  Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review , 2008, Journal of Neuro-Oncology.

[35]  G. Semenza,et al.  Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. , 2000, Cancer.